Menu Search
Equities

MoonLake Immunotherapeutics

MLTXN:MEX

MoonLake Immunotherapeutics

Actions
  • Price (MXN)686.81
  • Today's Change46.34 / 7.24%
  • Shares traded-1.00
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Jan 09 2024 11:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

  • Revenue in USD (TTM)0.00
  • Net income in USD-40.68m
  • Incorporated2020
  • Employees50.00
  • Location
    MoonLake ImmunotherapeuticsDorfstrasse 29ZUG 6300SwitzerlandCHE
  • Phone+41 415108022
  • Websitehttps://moonlaketx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.